These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

322 related articles for article (PubMed ID: 22829924)

  • 1. Modulation of MicroRNA-194 and cell migration by HER2-targeting trastuzumab in breast cancer.
    Le XF; Almeida MI; Mao W; Spizzo R; Rossi S; Nicoloso MS; Zhang S; Wu Y; Calin GA; Bast RC
    PLoS One; 2012; 7(7):e41170. PubMed ID: 22829924
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Epigenetic silencing of miR-375 induces trastuzumab resistance in HER2-positive breast cancer by targeting IGF1R.
    Ye XM; Zhu HY; Bai WD; Wang T; Wang L; Chen Y; Yang AG; Jia LT
    BMC Cancer; 2014 Feb; 14():134. PubMed ID: 24571711
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Trastuzumab produces therapeutic actions by upregulating miR-26a and miR-30b in breast cancer cells.
    Ichikawa T; Sato F; Terasawa K; Tsuchiya S; Toi M; Tsujimoto G; Shimizu K
    PLoS One; 2012; 7(2):e31422. PubMed ID: 22384020
    [TBL] [Abstract][Full Text] [Related]  

  • 4. MiR-199b-5p targets HER2 in breast cancer cells.
    Fang C; Zhao Y; Guo B
    J Cell Biochem; 2013 Jul; 114(7):1457-63. PubMed ID: 23296799
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Erythropoietin receptor expression and its relationship with trastuzumab response and resistance in HER2-positive breast cancer cells.
    Zhang C; Duan X; Xu L; Ye J; Zhao J; Liu Y
    Breast Cancer Res Treat; 2012 Dec; 136(3):739-48. PubMed ID: 23117856
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Posttranscriptional upregulation of HER3 by HER2 mRNA induces trastuzumab resistance in breast cancer.
    Li X; Xu Y; Ding Y; Li C; Zhao H; Wang J; Meng S
    Mol Cancer; 2018 Aug; 17(1):113. PubMed ID: 30068375
    [TBL] [Abstract][Full Text] [Related]  

  • 7. FOXO1A is a target for HER2-overexpressing breast tumors.
    Wu Y; Shang X; Sarkissyan M; Slamon D; Vadgama JV
    Cancer Res; 2010 Jul; 70(13):5475-85. PubMed ID: 20551062
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Poly (ADP-ribose) polymerase inhibition enhances trastuzumab antitumour activity in HER2 overexpressing breast cancer.
    García-Parra J; Dalmases A; Morancho B; Arpí O; Menendez S; Sabbaghi M; Zazo S; Chamizo C; Madoz J; Eroles P; Servitja S; Tusquets I; Yelamos J; Lluch A; Arribas J; Rojo F; Rovira A; Albanell J
    Eur J Cancer; 2014 Oct; 50(15):2725-34. PubMed ID: 25128455
    [TBL] [Abstract][Full Text] [Related]  

  • 9. miR‑135b‑5p enhances the sensitivity of HER‑2 positive breast cancer to trastuzumab via binding to cyclin D2.
    Li Z; Qin Y; Chen P; Luo Q; Shi H; Jiang X
    Int J Mol Med; 2020 Oct; 46(4):1514-1524. PubMed ID: 32700749
    [TBL] [Abstract][Full Text] [Related]  

  • 10. MicroRNA-7 inhibits multiple oncogenic pathways to suppress HER2Δ16 mediated breast tumorigenesis and reverse trastuzumab resistance.
    Huynh FC; Jones FE
    PLoS One; 2014; 9(12):e114419. PubMed ID: 25532106
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Antitumoral actions of the anti-obesity drug orlistat (XenicalTM) in breast cancer cells: blockade of cell cycle progression, promotion of apoptotic cell death and PEA3-mediated transcriptional repression of Her2/neu (erbB-2) oncogene.
    Menendez JA; Vellon L; Lupu R
    Ann Oncol; 2005 Aug; 16(8):1253-67. PubMed ID: 15870086
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Expression of miR-4324 and its targeted gene Talin2 in breast cancer].
    Gao P; Zhu H; Pei W; Xu P; Ding Y
    Nan Fang Yi Ke Da Xue Xue Bao; 2022 Oct; 42(10):1517-1525. PubMed ID: 36329586
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Chemotherapy-Regulated microRNA-125-HER2 Pathway as a Novel Therapeutic Target for Trastuzumab-Mediated Cellular Cytotoxicity in Small Cell Lung Cancer.
    Yagishita S; Fujita Y; Kitazono S; Ko R; Nakadate Y; Sawada T; Kitamura Y; Shimoyama T; Maeda Y; Takahashi F; Takahashi K; Tamura T; Koizumi F
    Mol Cancer Ther; 2015 Jun; 14(6):1414-23. PubMed ID: 25833836
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Specific blockade of VEGF and HER2 pathways results in greater growth inhibition of breast cancer xenografts that overexpress HER2.
    Le XF; Mao W; Lu C; Thornton A; Heymach JV; Sood AK; Bast RC
    Cell Cycle; 2008 Dec; 7(23):3747-58. PubMed ID: 19029832
    [TBL] [Abstract][Full Text] [Related]  

  • 15. miR-200c suppresses stemness and increases cellular sensitivity to trastuzumab in HER2+ breast cancer.
    Tang H; Song C; Ye F; Gao G; Ou X; Zhang L; Xie X; Xie X
    J Cell Mol Med; 2019 Dec; 23(12):8114-8127. PubMed ID: 31599500
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The microRNA-141-3p/ CDK8 pathway regulates the chemosensitivity of breast cancer cells to trastuzumab.
    Song W; Wu S; Wu Q; Zhou L; Yu L; Zhu B; Gong X
    J Cell Biochem; 2019 Aug; 120(8):14095-14106. PubMed ID: 31087707
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Up-regulation of miR-21 mediates resistance to trastuzumab therapy for breast cancer.
    Gong C; Yao Y; Wang Y; Liu B; Wu W; Chen J; Su F; Yao H; Song E
    J Biol Chem; 2011 May; 286(21):19127-37. PubMed ID: 21471222
    [TBL] [Abstract][Full Text] [Related]  

  • 18. MicroRNA-21 links epithelial-to-mesenchymal transition and inflammatory signals to confer resistance to neoadjuvant trastuzumab and chemotherapy in HER2-positive breast cancer patients.
    De Mattos-Arruda L; Bottai G; Nuciforo PG; Di Tommaso L; Giovannetti E; Peg V; Losurdo A; Pérez-Garcia J; Masci G; Corsi F; Cortés J; Seoane J; Calin GA; Santarpia L
    Oncotarget; 2015 Nov; 6(35):37269-80. PubMed ID: 26452030
    [TBL] [Abstract][Full Text] [Related]  

  • 19. HER2-positive breast cancer cells resistant to trastuzumab and lapatinib lose reliance upon HER2 and are sensitive to the multitargeted kinase inhibitor sorafenib.
    Valabrega G; Capellero S; Cavalloni G; Zaccarello G; Petrelli A; Migliardi G; Milani A; Peraldo-Neia C; Gammaitoni L; Sapino A; Pecchioni C; Moggio A; Giordano S; Aglietta M; Montemurro F
    Breast Cancer Res Treat; 2011 Nov; 130(1):29-40. PubMed ID: 21153051
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The microRNA-21/PTEN pathway regulates the sensitivity of HER2-positive gastric cancer cells to trastuzumab.
    Eto K; Iwatsuki M; Watanabe M; Ida S; Ishimoto T; Iwagami S; Baba Y; Sakamoto Y; Miyamoto Y; Yoshida N; Baba H
    Ann Surg Oncol; 2014 Jan; 21(1):343-50. PubMed ID: 24154840
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 17.